Biotech Archives - Page 57 of 795

2 minute read

Biogen/Eisai’s Popular Alzheimer’s Drug Leqembi Is Seeing Slow Adoption – Here’s Why

April 24, 2:23 PM

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA approval.

BIIB

2 minute read

What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk

By Vandana Singh

April 24, 2:14 PM

Senate Committee probes Novo Nordisk's pricing tactics for diabetes and obesity meds. Sanders demands transparency on pricing, signaling broader industry scrutiny. Medicare coverage expansion could impact millions, tackling accessibility challenges amidst rising costs.

LLY

2 minute read

Biogen’s Leqembi Commercial Ramp-Up Modest But Up Ticking, Reports Mixed Bag Q1 Earnings

By Vandana Singh

April 24, 12:12 PM

Biogen reports Q1 results: adjusted EPS $3.67 (beat consensus), sales $2.29 billion (missed consensus). Leqembi launch uptake triples, Zurzuvae's early trends encouraging.

BIIB

2 minute read

Results Of Novocure’s METIS Phase 3 Clinical Trial For Patients With Brain Metastasis From Non-Small Cell Lung Cancer To Be Presented As Late-Breaking Abstract At ASCO 2024

By Benzinga Newsdesk

April 24, 10:46 AM

Novocure (NASDAQ:NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology

NVCR

2 minute read

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?

By Vandana Singh

April 24, 10:43 AM

Immutep releases preliminary results from TACTI-003 trial showing promising outcomes for first-line treatment of HNSCC patients without PD-L1 expression. Final data expected in H1 CY2024.

IMMP

2 minute read

BioXcel Therapeutics Announces Late-Breaking Abstract On Preliminary Findings From Phase 2 Investigator-Sponsored Trial Of BXCL701 And KEYTRUDA In Metastatic Pancreatic Ductal Adenocarcinoma Selected For Presentation At 2024 ASCO Annual Meeting

By Benzinga Newsdesk

April 24, 10:33 AM

Poster presentation scheduled for June 1, 2024, 1:30-4:30 PM CT /2:30-5:30 PM ET Trial being led by Georgetown University's Lombardi Comprehensive Cancer CenterNEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) --

BTAI

1 minute read

Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?

By Vandana Singh

April 24, 10:31 AM

HOOKIPA Pharma secures FDA clearance for its innovative HB-700 therapeutic vaccine targeting KRAS-mutated cancers. Learn about its broad impact on lung, colorectal, and pancreatic cancers, achieving significant milestones in collaboration and intellectual property.

GILD

1 minute read

Precigen To Present Late-Breaking Abstract For Pivotal Phase 2 Study Data For PRGN-2012 AdenoVerse Immunotherapy For The Treatment Of Patients With Recurrent Respiratory Papillomatosis At The 2024 ASCO Annual Meeting

By Benzinga Newsdesk

April 24, 10:22 AM

Precigen, Inc. (NASDAQ:PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced clinical data from the pivotal Phase

PGEN

2 minute read

Cullinan Therapeutics To Present Clinical Data From Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, As Monotherapy And In Combination With A Checkpoint Inhibitor In Patients With Advanced Solid Tumors At ASCO 2024

By Benzinga Newsdesk

April 24, 10:10 AM

Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid

CGEM

4 minute read

Regeneron To Showcase Progress In Advancing Novel Investigational Treatment Approaches For A Broad Range Of Solid Tumors And Blood Cancers At ASCO

By Benzinga Newsdesk

April 24, 10:06 AM

Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo®

REGN